2026
October
New PrimeCAR protocol delivers improved CAR T cells in less time
October 21, 2026
CAR T cells are a powerful treatment option for certain cancers, but their use can be limited by long manufacturing times and severe toxicities. In order to overcome these hurdles, Yang and Li et al. developed a new CAR T cell manufacturing protocol called PrimeCAR involving low-intensity priming with cytokine support and limited...
Checkpoints for the win: neoadjuvant ICB outperforms targeted therapy in melanoma
October 14, 2026
Neoadjuvant treatment with immunotherapy and/or targeted agents has become standard of care for resectable stage IIIB-D melanoma. However, the optimal treatment regimen and the consequences for long-term survival remain largely unknown. Long et al. analyzed a large dataset of patients treated with immune and/or targeted neoadjuvant treatments to answer some of these outstanding...
T-RAP – a new tool for predicting TCR-pMHC reactivity
October 7, 2026
Predicting TCR-pMHC reactivity is useful for a variety of immunotherapy research tasks, including identifying relevant neoantigens and developing vaccines. In work recently published in Immunity, Messemaker and Kwee et al. developed a TCR rapid assembly platform (T-RAP) and used it to generate a dataset of functionally validated TCR-pMHC pairs, which enabled the assembly...
